Payment overview · 2025
General Payments
$256.65
11 reported records · 8 companies
Healthcare provider profile · identity verified
Loan Dao, MD
Allopathic & Osteopathic Physicians|Family Medicine · ESCONDIDO, CA · NPI 1063670966
Verified facts
What the public records show
CMS Open Payments records show Loan Dao, MD received $256.65 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.17 | 30.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.89 | 21.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.46 | 11.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.95 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.29 | 9.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.55 | 7.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.50 | 5.7% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $9.84 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.65 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.17 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $54.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 257 | 73 |
| Metformin Hcl | Metformin Hcl | 239 | 68 |
| Gabapentin | Gabapentin | 204 | 37 |
| Lisinopril | Lisinopril | 195 | 60 |
| Losartan Potassium | Losartan Potassium | 190 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 42 |
| Eliquis | Apixaban | 120 | 22 |
| Simvastatin | Simvastatin | 90 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 18 |
| Furosemide | Furosemide | 75 | 27 |
| Potassium Chloride | Potassium Chloride | 71 | 23 |
| Atenolol | Atenolol | 70 | 21 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 20 |
| Sertraline Hcl | Sertraline Hcl | 59 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 18 |
| Mirtazapine | Mirtazapine | 52 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 18 |
| Omeprazole | Omeprazole | 48 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Jardiance | Empagliflozin | 47 | 13 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Hydrocortisone | Hydrocortisone | 39 | 20 |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Prednisone | Prednisone | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Nystop | Nystatin | 25 | 11 |
| Risperidone | Risperidone | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Digoxin | Digoxin | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.65 · 11 records | Novo Nordisk Inc | EVENITY, KISUNLA, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, WaveWriter Alpha Prime 16, bio-ConneKt | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error